---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-017031"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:08:30.551048+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience reports Q1 2023 FYARRO sales of $5.9M, net loss $15.2M; PRECISION 1 interim analysis expected end 2023

## Summary
- FYARRO net product sales $5.9M, up 12% QoQ from $5.2M in Q4 2022 and $2.3M in Q1 2022.
- Net loss $15.2M vs $13.9M in Q1 2022; cash $151.2M expected to fund operations into 2025.
- PRECISION 1 trial enrolling evenly in TSC1/2 arms; >15 tumor types; interim efficacy analysis on 40 patients expected by year-end 2023.
- Appointed Dr. Mohammad Hirmand to board; Phase 1/2 KRAS G12C combo trial with adagrasib expected to start dosing in Q2 2023.

## SEC filing metadata
- accession: 0001628280-23-017031
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/0001628280-23-017031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/aadi-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-017031
- JSON: https://secwatch.observer/filing/0001628280-23-017031.json
- Plain text: https://secwatch.observer/filing/0001628280-23-017031.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $5.9 million, net income $15.2 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: $5.9 million
  - Net income: $15.2 million
  - Result: reported results
  source text: Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 40 patients with appropriate
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/0001628280-23-017031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.